Skip to main content

Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference

Written by Customer Service on . Posted in Public Companies.

April events to highlight Longeveron’s commitment to developing cell therapeutics for chronic aging related diseases.

MIAMI, April 14, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today its Chief Science Officer, Co-Founder, and Chairman, Joshua Hare, M.D., F.A.C.C., F.A.H.A. will be presenting at the Longevity Leaders World Congress in April. Also this month, Longeveron Director of Medical Affairs Kevin N. Ramdas, M.D. M.P.H. will present at the upcoming 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) as well as the 3rd Annual Latinos & Alzheimer’s Symposium hosted by the Alzheimer’s Association, where Longeveron’s Senior Scientist, Anthony Oliva, PhD will also moderate and present two oral communications.

Details of Longeveron’s participation at these events are as follows:

  • 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR)
    Title: Biomarker Results from a Phase 2b Clinical Trial Assessing Lomecel-B Infusion in Older Adults with Frailty
    Format: Live oral presentation by Kevin N. Ramdas, M.D., M.P.H., Director of Medical Affairs
    Date: April 20, 2022
    Time: 4:20 p.m. ET
    Location: Boston, Massachusetts
  • 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR)
    Title: Lomecel-B as a Geroscience Therapeutic Candidate for Cognitive Frailty
    Format: Moderating and presentation by Anthony A. Oliva, PhD, Senior Scientist
    Date: April 21, 2022
    Time: 12:00 p.m. ET
    Location: Boston, Massachusetts
  • 3rd Latinos & Alzheimer’s Symposium
    Title: Diversity, equity and inclusion in a phase 1 clinical trial assessing Lomecel-B in patients with Alzheimer’s disease
    Format: Poster session presented by Kevin N. Ramdas, M.D., M.P.H., Director of Medical Affairs
    Poster Number: 68512
    Date: April 25, 2022
    Time: 12:45 ET
    Location: Bonita Springs, Florida
  • Longevity Leaders World Congress
    Title: Advancing aging frailty through the clinic with ageing clinical endpoints
    Format: Live oral presentation by Joshua Hare, M.D., F.A.C.C., F.A.H.A., Co-Founder, Chief Science Officer, and Chairman
    Date: April 26, 2022
    Time: 1:40 p.m. GMT (9:40 a.m. ET)
    Location: London, United Kingdom
  • Longevity Leaders World Congress
    Title: Translating and commercializing regenerative medicine and ageing science into therapeutics and consumer products
    Format: Live panel with participation from Joshua Hare, M.D., F.A.C.C., F.A.H.A., Co-Founder, Chief Science Officer, and Chairman
    Date: April 26, 2022
    Time: 3:45 p.m. GMT (10:45 p.m. ET)
    Location: London, United Kingdom

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

Contact:
Brendan Payne
Stern Investor Relations
Tel: (212) 362-1200
Email: Brendan.payne@sternir.com

Source: Longeveron

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.